Quick Facts

• Relief of Symptoms: Helps manage pain, swelling, and inflammation associated with certain conditions.
• Joint Conditions: Used for the symptomatic relief of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
• Acute Pain: Indicated for short-term management of acute gouty arthritis and moderate post-operative dental pain.

---

What Algix Treats: Main Uses and Benefits

Algix is administered for the management of pain and inflammation related to various musculoskeletal and joint conditions. Its primary role involves providing symptomatic relief for individuals managing rheumatoid arthritis, which is an autoimmune condition causing joint inflammation, and osteoarthritis, a condition marked by the breakdown of joint cartilage.

The medication is also utilized to help lessen the symptoms associated with ankylosing spondylitis, a form of arthritis that primarily affects the spine. Additionally, Algix may be prescribed for the short-term control of pain and signs of inflammation associated with acute gouty arthritis, which is a condition characterized by sudden, severe attacks of pain and swelling in the joints. It is also used to help provide temporary pain relief following certain dental surgical procedures.

Algix is considered a relevant treatment option in the context of these conditions, helping to support patient comfort and movement.

Regulatory References

1. EMA therapeutic overview

Official Regulatory Eligibility Profile

Eligibility for Algix is strictly determined by documented contraindications and restrictions related to specific health conditions, age, and physiological states, as defined by government regulatory authorities.

Eligibility Status	Specific Exclusion Criteria
Contraindicated Use	History of hypersensitivity to Algix or similar NSAIDs (including allergic reactions, asthma, or acute rhinitis). Active gastrointestinal bleeding or peptic ulceration. Severe heart failure (NYHA Class II-IV), established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. Uncontrolled hypertension (persistently above 140/90 mmHg). Severe hepatic or renal impairment.
Not Recommended	Pregnancy and lactation. Children and adolescents under 16 years of age (safety and efficacy not established). Patients with inflammatory bowel disease.

Age and Life Stage: Algix is contraindicated in children and adolescents under 16 years. Use is also contraindicated during pregnancy and lactation. Older adults require careful consideration and the use of the lowest effective dose due to increased risk factors.

Restrictions: Eligibility is conditional. For all eligible patients, use must be limited to the shortest possible duration at the lowest effective daily dose. Patients with cardiovascular risk factors, or mild to moderate hepatic dysfunction, must have their use closely monitored and may be subject to maximum dose restrictions.

The interaction profile of Algix (Etoricoxib) is defined by its potential to alter the exposure of co-administered medicines and by specific pharmacodynamic constraints documented in regulatory labeling.

Interaction-Related Restrictions

Restriction Classification	Interacting Agent	Official Constraint
Not Recommended	Other NSAIDs and selective COX-2 inhibitors	Increased risk of gastrointestinal adverse effects.
Not Recommended	Aspirin (Acetylsalicylic acid) at analgesic doses	Increased risk of gastrointestinal complications.
Use with Caution	Oral Anticoagulants (e.g., Warfarin)	Requires close monitoring of International Normalized Ratio (INR).
Use with Caution	Lithium	Requires close monitoring of plasma lithium levels.

Documented Exposure and Pharmacodynamic Effects

• Oral Contraceptives: Etoricoxib significantly increases the systemic exposure ( AUC) of the oral contraceptive component Ethinyloestradiol (EE) by 50% to 60%, requiring consideration when selecting an oral contraceptive.
• Metabolic Induction: Co-administration with the potent hepatic enzyme inducer Rifampicin results in a 65% decrease in Etoricoxib AUC (exposure), which may compromise effectiveness.
• Antihypertensives: Etoricoxib may diminish the antihypertensive effect of Diuretics, ACE Inhibitors, and ARBs. In patients with compromised renal function (such as the elderly or volume-depleted), this combination may lead to reversible deterioration of renal function.

Food Interaction Note

Administration with food does not affect the total amount of drug absorbed, but it does affect the rate of absorption. Taking Algix without food may result in a faster onset of effect, a factor to be considered when rapid symptomatic action is required.

How Algix Works

Algix functions as a highly selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. Its mechanism involves the molecule reversibly binding to the enzyme's catalytic site, disabling its function in converting Arachidonic Acid into prostanoids. The strong binding affinity for COX-2 results in a preferential effect on tissues where this enzyme is upregulated, while minimally disrupting the COX-1 isoform, which is essential for regulating homeostatic processes such as gastric mucosal integrity. By blocking COX-2, the drug interrupts the Arachidonic Acid Cascade, specifically reducing the synthesis and release of pro-inflammatory mediators, primarily Prostaglandin E2 ( PGE2). This reduction diminishes the chemical signals responsible for processes like capillary permeability and swelling, leading to a modulation of the systemic inflammatory response. Furthermore, decreased PGE2 concentration at nerve terminals reduces the sensitization of peripheral nociceptors. The physiological outcome is an increase in the firing threshold for nociceptive signal transmission, stabilizing input to the central nervous system.

Algix (Etoricoxib) is administered orally as a film-coated tablet in multiple strengths, ranging from 30 mg up to 120 mg. All official regimens are administered once daily (QD). The standard usage protocol involves using the lowest effective daily dose for the shortest duration possible.

Standard Labeled Dosing Regimens

The maximum recommended daily dose is dependent on the condition being addressed:

Indication	Recommended Daily Dose	Maximum Daily Dose	Duration Constraint
Osteoarthritis (OA)	30 mg to 60 mg	60 mg	Periodic re-evaluation
Rheumatoid Arthritis (RA) & Ankylosing Spondylitis (AS)	60 mg to 90 mg	90 mg	Periodic re-evaluation
Acute Gouty Arthritis	120 mg	120 mg	Limited to 8 days
Postoperative Dental Pain	90 mg	90 mg	Limited to 3 days

The tablet may be taken with or without food. Administration without food may result in a faster onset of effect, which is a factor to consider when rapid symptomatic relief is required.

Population-Specific Constraints

Use is authorized for adults and adolescents 16 years of age and older. No dosage adjustment is necessary for older adults. Dose caps are enforced for hepatic impairment: patients with mild impairment (Child-Pugh 5–6) must not exceed 60 mg once daily, and those with moderate impairment (Child-Pugh 7–9) are restricted to a maximum of 30 mg once daily. In the event a dose is missed, the next dose should be taken at the regularly scheduled time without doubling the dose.

Research evidence / Overview of studies for Algix

Evidence for Use in Chronic Joint Conditions

Algix (Etoricoxib) was studied for the symptomatic study of chronic joint disorders, primarily Osteoarthritis (OA) and Rheumatoid Arthritis (RA), which are conditions marked by functional limitations and systemic or functional imbalance. The research base for these uses largely relies on Randomized Controlled Trials (RCTs) that included comparisons to an inactive substance (placebo) or another agent studied in the same context. These trials generally included large numbers of adults, sometimes including older individuals, experiencing symptoms related to these conditions.

In the studies focused on OA, research examined outcomes related to physical discomfort, such as pain intensity and joint stiffness, as well as outcomes reflecting daily functioning or activity level. Findings included the measurement of changes in pain and function compared to the baseline condition, as reported by patients over the initial weeks of study. For RA, studies monitored outcomes capturing phases of heightened symptom activity, such as the count of swollen or tender joints. Research findings included the documentation of observed changes in these metrics across the study duration.

Evidence for Use in Ankylosing Spondylitis and Acute Pain

Research also explored the medicine's role in short-term symptom changes for specific acute conditions. For Acute Gouty Arthritis, studies focused on episodes where symptoms become more noticeable, examining outcomes describing episodic or acute changes such as joint swelling and intense pain over a very short time interval (typically less than two weeks). Similarly, for Post-Operative Dental Pain, studies were conducted during periods of increased symptom activity following surgery, monitoring outcomes related to short-term changes over the first 24 hours. Findings described group patterns of outcome measures observed during these acute research scenarios.

What Remains Uncertain and Future Research Gaps

Follow-up durations were limited in many core efficacy trials, meaning that sustained outcomes for periods beyond one year are not fully established from controlled research. The research record does include very large observational studies that described patterns of usage and measured outcomes observed in patient groups over extended periods. However, long-term effects on the continued study of pain and function are not fully established by the core research. The evidence is primarily focused on the study of symptom manifestation or change, and the research available does not provide insight into potential disease modification for conditions like OA or RA.

Common questions about Algix (FAQ)

Q: What is Algix used for besides the main condition?

Official labeling describes Algix's purpose as the symptomatic relief of pain and inflammation across five different conditions. These include chronic joint disorders such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also indicated for short-term symptom relief in cases of Acute Gouty Arthritis and Postoperative Dental Pain.

Q: Is Algix the same type of medicine as ibuprofen?

Algix is classified as a selective Cyclooxygenase-2 (COX-2) inhibitor, which is a specific type of Nonsteroidal Anti-inflammatory Drug (NSAID). While both belong to the NSAID class, Algix is distinguished by its focused mechanism of primarily blocking the COX-2 enzyme.

Q: How long does the effect of Algix last?

Official pharmacokinetic studies indicate the medicine has an elimination half-life of approximately 20 hours in healthy adults. This long half-life supports the medicine’s once-daily dosing regimen, allowing for sustained effects throughout the day.

Q: Can Algix affect my sleep?

The official regulatory documentation lists Insomnia (difficulty sleeping) as an Uncommon adverse effect, meaning it is seen in less than 1 in 100 people. If any changes in sleep patterns are experienced, they are noted in the safety profile.

Q: Is Algix considered a strong pain reliever?

Algix is described in regulatory documents for the symptomatic relief of pain and inflammation associated with its approved conditions. The official labeling uses neutral terminology and does not use subjective terms such as “strong” to categorize the level of relief provided.

Q: Do studies show Algix is effective for chronic pain?

The research base includes Randomised Controlled Trials (RCTs) for chronic joint conditions like Osteoarthritis and Rheumatoid Arthritis. Findings documented measured changes in pain intensity and functional ability in these patient groups, consistent with symptomatic relief.

Q: What should I do if a side effect is bothering me?

If a side effect becomes bothersome or you have concerns about your medicine, patients are generally advised to discuss these symptoms or questions with their prescribing doctor or a pharmacist. This allows the healthcare professional to review the symptoms.

Q: Is Algix a habit-forming or addictive medicine?

Algix is classified as a selective COX-2 inhibitor, a type of Nonsteroidal Anti-inflammatory Drug (NSAID). This class of medication is not associated with dependency or addiction risk.

Q: Are there warnings about driving while using Algix?

The official product information lists dizziness and headache as Common side effects. Official product information advises caution regarding driving or operating machinery if the patient experiences side effects such as dizziness, fatigue, or other alterations in their ability to concentrate.

Q: What does it mean if Algix has a 'Black Box Warning'?

A Black Box Warning is the strongest regulatory alert used in the United States to draw attention to serious risks associated with a medicine. The documentation for all NSAIDs includes warnings about the potential for serious cardiovascular and gastrointestinal events.

Q: Does Algix interact with common over-the-counter pain medicines?

Official labeling advises that Algix is Not Recommended for use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin at analgesic doses. This is due to an increased risk of gastrointestinal side effects when these medicines are used concurrently.

Q: Is there a generic version of Algix available?

Algix is the trade name for the active ingredient Etoricoxib. Etoricoxib is the non-proprietary name for this medicinal entity.

Q: Can Algix cause weight gain or loss?

The medicine is officially documented to cause fluid retention (oedema) as a Common adverse reaction. Fluid retention is a factor that can potentially result in changes in body weight.

Q: Why is Algix not used to treat fevers?

The official purpose of Algix is to provide symptomatic relief from pain and inflammation. The safety information documented by regulatory authorities notes that the medicine may mask fever and other diagnostic signs, as it may complicate the detection of an underlying infection.

Q: Is Algix effective for nerve pain?

The mechanism of action is described as reducing the sensitization of peripheral nociceptors, which are nerve cells that respond to pain. While this relates to pain transmission, the official indications for Algix do not include the treatment of specific neuropathic pain conditions.

Q: What does 'contraindicated' mean for Algix?

The term contraindicated is used by regulatory authorities to describe specific conditions, health problems, or patient groups for which the medicine should not be used. This means that for these situations, the risks are considered to outweigh any potential benefit.

Q: How is Algix different from Tylenol (acetaminophen)?

Algix is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by inhibiting the COX-2 enzyme to reduce inflammation. Acetaminophen is a different class of medicine that works through a distinct mechanism and does not possess significant anti-inflammatory properties.

Q: Is there a link between Algix and ringing in the ears (tinnitus)?

Ringing in the ears (Tinnitus) is listed in the official documentation as an Uncommon adverse effect. This means it has been reported in less than 1 in 100 people using the medicine.

Q: Do the effects of Algix build up over time?

Due to its long half-life of approximately 20 hours, the concentration of the medicine in the body will gradually increase with continued daily dosing. This accumulation continues until it reaches a stable concentration known as steady state.

Q: What is the half-life of Algix?

Pharmacokinetic studies indicate that the medicine has an elimination half-life of approximately 20 hours in healthy adults. This measure reflects the time it takes for half of the dose to be eliminated from the body.

Q: Are there any long-term safety studies on Algix use?

While the core efficacy trials had limited follow-up, the research base includes very large observational studies that described usage patterns over extended periods. Official guidance recommends limiting use to the shortest duration possible, as risks may increase with dose and duration.

Q: Can Algix be crushed or chewed?

Algix is supplied as a film-coated tablet and is intended to be swallowed whole with a glass of water. Official guidance indicates that patients should not crush, chew, or split the tablets, as this may affect the medicine’s absorption.

Q: Does Algix interact with antidepressants?

Official documents note that the co-administration of Algix with certain types of antidepressants, specifically SSRIs, is associated with an increased risk of gastrointestinal bleeding. Regulatory documents note that co-administration may require patient monitoring by a healthcare provider.

Official Storage and Disposal Instructions for Algix

To maintain the quality and safety of this medication, Algix must be stored and handled strictly according to the official label requirements.

Storage Requirement	Official Guidance
Temperature	Do not store above 30 C.
Protection	Store in the original container and keep the container tightly closed to protect the contents from moisture.
Handling	Keep in the original container. Storage and handling must prevent contamination of water, food, or feed.

Disposal of Algix:

Disposal must be conducted in a manner that ensures protection of public health and safety and avoids any risk to the environment. Do not contaminate water, food, or feed by storage or disposal of this product. Consult your local medication take-back program or pharmacy for the most appropriate disposal guidance in your area.